On November 1, 2023 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported the Company will present four posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA (Press release, BostonGene, NOV 1, 2023, View Source [SID1234636681]). BostonGene will also exhibit at booth 639.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BostonGene session details are below:

Abstract: 143
Title: Correlating RNA-Seq Detection and IHC Staining of Potential ADC Targets: HER3, TROP2, Nectin4 and aFLR
Date and time: Friday, November 3 | 12:00 PM – 1:30 PM and 5:10 PM – 6:40 PM
Location: Exhibit Hall B
Presenter: Alexander Bagaev, PhD, BostonGene

This study showed that the IHC results of five promising ADC targets (HER3, HER2, TROP2, Nectin4, and aFLR) correlated with their RNA sequencing (RNA-seq) gene expression values, highlighting the potential use of RNA-seq to detect ADC targets.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center

Abstract: 555
Title: Challenges in Predicting ICI Response in HPV+ HNSCC: Insights into the Tumor Microenvironment
Date and time: Friday, November 3 | 12:00 PM – 1:30 PM and 5:10 PM – 6:40 PM
Location: Exhibit Hall B
Presenter: Anastasia Nikitina, PhD, BostonGene

Transcriptomic analysis of human papillomavirus (HPV)+ head and neck squamous cell carcinomas (HNSCCs) revealed a disparity in underlying mechanisms of ICI response, particularly related to the tumor microenvironment (TME), between HPV- and HPV+ HNSCC patients. This study underscores the importance of considering a patient’s HPV status when assessing mechanisms associated with ICI response in HNSCC.

Research conducted in collaboration with Thomas Jefferson University

Abstract: 222-K
Title: Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)
Date and time: Saturday, November 4 | 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM
Location: Exhibit Hall B
Presenter: Michael Goldberg, PhD, BostonGene

In this study, immunoprofiling of peripheral blood cells in combination with RNA-seq of tumor tissues identified novel predictors of anti-PD-1 response in HNSCC, suggesting the utility of this integrated approach as a tool to develop biologic predictors of ICI response that can lead to more effective personalized treatment options for cancer patients.

Research conducted in collaboration with Thomas Jefferson University

Abstract: 532
Title: A Cross-Cohort Examination of Factors Impacting Immunotherapy Survival in Non-Small Cell Lung Cancer (NSCLC)
Date and time: Saturday, November 4 | 11:55 AM – 1:25 PM and 7:00 PM – 8:30 PM
Location: Exhibit Hall B
Presenter: Nikita Kotlov, BostonGene

BostonGene’s transcriptome-based TME classification approach and proprietary cell deconvolution tool Kassandra were used to identify the TME subtypes and characterize the TME cell types of NSCLC patients treated with ICIs. The results showed that the TME subtypes and CD8+ T cell infiltration were associated with overall and progression-free survival, indicating their potential as predictive biomarkers for immunotherapy response.

Research conducted in collaboration with St Luke’s Cancer Institute

To learn more or to schedule a meeting with BostonGene during SITC (Free SITC Whitepaper), please contact Maria Proia at [email protected].

On November 1, 2023 Prelude Therapeutics Incorporated ("Prelude") (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) reported a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer (Press release, Prelude Therapeutics, NOV 1, 2023, View Source [SID1234636680]). The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera’s antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs). The first program, which benefits from a lead panel of antibodies previously discovered by AbCellera, is focused on ADCs to broaden the reach of Prelude’s small molecule SMARCA2 selective degraders to address a larger patient population.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"By leveraging our combined capabilities and expertise in rapidly discovering and advancing novel candidates into the clinic, this collaboration provides an opportunity to build a pipeline of first-in-class ADCs targeting clinically validated pathways in oncology," said Kris Vaddi, Ph.D., Founder and CEO of Prelude.

"Through this strategic partnership we are combining deep expertise in antibody and small molecule development to create precision ADC therapies for patients in need," said Carl Hansen, Ph.D., Founder and CEO of AbCellera.

Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration. AbCellera will lead manufacturing activities and Prelude will lead clinical development and global commercialization, subject to AbCellera’s option to co-promote any resulting commercial products in the United States.

On November 1, 2023 I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, reported that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company’s 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 1-5, 2023, in San Diego, California (Press release, I-Mab Biopharma, NOV 1, 2023, View Source [SID1234636679]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full text of the abstracts has been released on the SITC (Free SITC Whitepaper) website, and the posters will be available on the Company’s website following the conclusion of SITC (Free SITC Whitepaper) 2023. Details of the poster presentations are as follows:

Title:

Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

Poster #:

792

Presenter:

Dr. Xuejun Liu, I-Mab

Date/Time:

Saturday, November 4, 2023

9:00 a.m. – 8:30 p.m. Pacific Time (12:00 p.m. – 11:30 p.m. Eastern Time)

Full abstract

View Source

Title:

ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade

Abstract ID:

845

Presenter:

Dr. Jaeho Jung, ABL Bio

Date/Time:

Friday, November 3, 2023

9:00 a.m. – 7:00 p.m. Pacific Time (12:00 p.m. – 10:00 p.m. Eastern Time)

Full abstract

View Source

About Givastomig

Givastomig, also known as TJ-CD4B/ABL111, is a bispecific antibody designed to bind to Claudin 18.2 (CLDN18.2) as a tumor engager and 4-1BB as a conditional T-Cell activator. It binds to tumor cells expressing various levels of CLDN18.2, i.e., gastric cancer and pancreatic cancer cells, and conditionally activates intra-tumoral T cells at the tumor site through the 4-1BB arm. Givastomig appears to effectively maintain a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both CLDN18.2 antibody and 4-1BB antibody while avoiding or minimizing liver toxicity and systemic immunotoxicity commonly seen with 4-1BB antibodies as a drug class. Being developed under collaboration between I-Mab and ABL Bio, a clinical-stage biotechnology company in South Korea, givastomig is currently being investigated in a Phase 1 clinical study in the U.S. and China. In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer, including cancer of the gastroesophageal junction.

About TJ-L14B/ABL503

Being developed jointly with ABL Bio (Kosdaq: 298380, hereafter "ABL"), TJ-L14B/ABL503 is a differentiated PD-L1-based bispecific antibody with the PD-L1 arm as the tumor-dependent T-cell activator and the 4-1BB arm as the conditional T cell activator upon tumor engagement. Using ABL’s "Grabody-T" bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity. Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination. A Phase 1 study is currently being conducted in the U.S. and South Korea.

On November 1, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of six studies at the upcoming SITC (Free SITC Whitepaper) (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California (Press release, Lunit, NOV 1, 2023, View Source [SID1234636678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During this year’s meeting, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

A collaborative study with the Samsung Medical Center assessed tumor-infiltrating lymphocytes (TILs) using AI-powered spatial analysis with Lunit SCOPE IO in EGFR-mutated non-small cell lung cancer (NSCLC) patients pre- and post-tyrosine kinase inhibitors (TKI) treatment. The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes. Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment. The study found that inflamed immune phenotype after EGFR-TKI treatment showed a higher overall response (OR; 40.0% vs. 7.5%) and better progression-free survival (PFS; 4.1 vs. 1.4 months) than other immune phenotype groups (excluded and desert type) to ICI treatment.

In another study, Lunit assessed the distribution of TILs in six subtypes of triple-negative breast cancer (TNBC) and their association with driver mutations. By analyzing The Cancer Genome Atlas breast cancer dataset using Lunit SCOPE IO, the study found that the immunomodulatory (IM) subtype of TNBC has a significantly higher mean intratumoral (iTIL), stromal (sTIL), and total TIL (tTIL) score than other TNBC subtypes. Additionally, TNBC samples with PIK3CA mutation/amplification or PTEN loss and BRCA1 or BRCA2 mutation each showed a higher total TIL score than those without mutation. This demonstrates that the TIL distribution can be a valuable biomarker for navigating the optimal treatment strategy in TNBC.

Lunit also explored the correlation between methylation burden and AI-based immune phenotype in The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset, which included 22 tumor types and a total of 6243 samples. The study found that the degree of methylation aberrancy in cancer is linked with TIL infiltration in the tumor microenvironment (TME) assessed by Lunit SCOPE IO.

Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME. In the study, a total of 7,472 TCGA H&E whole-slide images across 23 cancer types were analyzed with Lunit SCOPE IO. The study found that tumors with high TFI are closely correlated with high fibroblast infiltration but showed low IFNG, IL1A, and IL17A, genes that trigger inflammation as cancer grows.

"We are excited to be back to this year’s SITC (Free SITC Whitepaper) with our six groundbreaking studies that demonstrate the potential of our Lunit SCOPE suite in guiding treatment strategies for NSCLC and TNBC. We’ve also found valuable biomarkers and correlations that could lead to predictive information about patients’ immune response and the metastatic potential of the cancer tumor," said Brandon Suh, CEO of Lunit. "Through our participation in the SITC (Free SITC Whitepaper) conference, we will continue to back the efficacy of our Lunit SCOPE suite. At the same time, we are committed to seeking collaborations with healthcare giants worldwide to further our mission of advancing tailored cancer treatment."

Visit Lunit’s booth at SITC (Free SITC Whitepaper) 2023 at Booth #227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].

Lunit’s Abstracts at SITC (Free SITC Whitepaper) 2023

No.

Abstract
No. #

Title

Type

1

202

Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment in non-small cell lung cancer patients who have resistance after EGFR tyrosine kinase inhibitors

Poster

2

961

Tumor-infiltrating lymphocytes in tumor microenvironment assessed by artificial intelligence powered H&E image analyzer is correlated with immunomodulatory subtype of triple-negative breast cancer

Poster

3

1446

Pan-cancer methylation analysis reveals a significant correlation of immune-desert phenotype with methylation aberrancy

Poster

4

1293

Fragmented pattern of tumor mass is related to fibroblast activation mitigating spatial interaction between tumor and immune cells

Poster

5

1308

Artificial intelligence (AI)-powered immune phenotyping based on programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) in triple negative breast cancer (TNBC)

Poster

6

614

Safety and efficacy of YBL-006, a novel anti-PD-1 antibody, in advanced solid tumors including G3 NET/NEC: Results from a phase 1/2a study

Poster

On November 1, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023 (Press release, Ideaya Biosciences, NOV 1, 2023, View Source [SID1234636677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies London Healthcare Conference
Tuesday, November 14th, 2023 at 8:00 AM GMT | 3:00 AM ET

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
IDEAYA Biosciences Investor R&D Day
Monday, December 4th, 2023 at 8:00 AM ET

The IDEAYA Investor R&D Day will include participation from GSK and a key opinion leader that will showcase scientific insights and clinical development opportunities across IDEAYA’s synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, and the GSK partnered programs. In addition, IDEAYA will highlight its next generation initiatives in MTAP-deletion, including a wholly-owned program where a development candidate nomination is targeted in 2024, further advancing IDEAYA’s multi-pronged strategy.

Pre-registration will be available through IDEAYA’s investor relations events page at View Source
A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source. A replay of available webcasts will be accessible for 30 days following the live event.